Skip to content
HowShorted

Sarepta Therapeutics, Inc. short interest in 2020

In 2020, Sarepta Therapeutics, Inc.'s disclosed short interest ran from 16.98% of shares outstanding on 15 Jan 2020 to 8.95% on 31 Dec 2020, a change of -8.03 percentage points. The year's high was 16.98% on 15 Jan 2020 and its low 8.95% on 31 Dec 2020, averaging 13.67% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 25.05 days on 14 Feb 2020. Full history: Sarepta Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Sarepta Therapeutics, Inc. in 2020

2020 in figures

Start of year
16.98% (15 Jan 2020)
End of year
8.95% (31 Dec 2020)
Change
-8.03 pp
High
16.98% (15 Jan 2020)
Low
8.95% (31 Dec 2020)
Average
13.67%
Highest days to cover
25.05 (14 Feb 2020)
SEC filings marked
5

Every report in 2020

Sarepta Therapeutics, Inc. short interest in 2020
SettlementShort interestDays to coverFilings since previous
15 Jan 202016.98%14.26results (8-K)
31 Jan 202016.82%13.50
14 Feb 202016.93%25.05
28 Feb 202016.88%13.9410-K filed
13 Mar 202016.98%14.51
31 Mar 202016.66%13.09
15 Apr 202015.90%13.60
30 Apr 202015.46%17.33
15 May 202014.82%14.2910-Q filed
29 May 202014.96%11.42
15 Jun 202015.17%13.87
30 Jun 202013.67%10.41
15 Jul 202013.38%19.54
31 Jul 202012.83%16.71
14 Aug 202012.44%18.5610-Q filed
31 Aug 202012.05%12.48
15 Sep 202011.55%11.58
30 Sep 202011.62%14.19
15 Oct 202011.29%19.13
30 Oct 202011.17%23.39
13 Nov 202010.49%7.1510-Q filed
30 Nov 202011.03%21.49
15 Dec 202010.02%9.79
31 Dec 20208.95%11.15

See also: Sarepta Therapeutics, Inc.'s full history · most shorted US stocks of 2020 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.